The AIM Pharmaceutical’s “Oxyphylla A” treatment was officially signed and launched in Wuxi on August 9 during the “2025 Wuxi-Hong Kong Conference on Integrated Development of Technological and Industrial Innovation.” The project had previously established a cooperation intention with relevant government departments in Wuxi, and further deepened exchanges through the “𝐘-𝐋𝐎𝐓 Wuxi-Hong Kong SciTech Exchange Tour” in April this year, ultimately leading to this signing after several months of efforts.
This innovative medical project focuses on the development of treatment solutions for neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, and has received a funding of 100 million HKD from Hong Kong’s RAISe+ programme administered by the Innovation and Technology Commission. With the establishment of a research and development center in Wuxi, the clinical translation of related innovative therapies will be accelerated. 𝐘-𝐋𝐎𝐓 has long supported research projects with translational potential and witnesses this innovative research reaching an important milestone towards industrialization, looking forward to its research results opening new horizons for global neurodegenerative disease treatment.
「智仁藥業神經營養素項目」於8月9日「2025錫港科技創新和產業創新融合發展大會」上正式簽約落地無錫。該項目此前已與無錫市相關政府部門建立合作意向，並在今年4月透過「𝐘-𝐋𝐎𝐓錫港創科交流團」進一步深化交流，最終經過數月努力之後促成此次簽約。
此創新醫療項目專注於帕金森症及阿茲海默症等神經退化性疾病的治療方案研發，已獲香港創新科技署「產學研1+計劃」1億港元資助。隨著研發中心在無錫的設立，將加速推進相關創新療法的臨床轉化應用。𝐘-𝐋𝐎𝐓長期支持具有轉化潛力的科研項目，見證此項創新研究邁向產業化的重要里程碑，期待其研究成果能為全球神經疾病治療開拓新視野。
